Corporate COVID-19 Response Must Look Beyond Poison Pills

By Jim Woolery, Keith Townsend, Cal Smith, Rich Fields and Matthew Saur
May 1, 2020, 5:56 PM EDT

After years of tremendous economic growth, COVID-19 has unleashed unprecedented market volatility and extreme value dislocations for U.S. public companies. Senior management and directors are facing existential business model, strategic and...

Already a subscriber? Click here to view full article